1. Scrip
  2. >>Business

Argenx Takes Slow But Steady Approach To Vyvgart Sales

Amid Pandemic-Related And Educational Blocks

 
• By Ayisha Sharma

Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.  

Blocks with shopping trolleys representing sales
Vyvgart Sales May Not Be As High As Rival Soliris Off The Bat • Source: Alamy

argenx N.V. is having to take a gradual approach to growing Vyvgart sales as the generalized myasthenia gravis (gMG) product faces hurdles from the COVID-19 pandemic and the lack of medical education on the drug’s target, FcRn.

The US Food and Drug Administration gave Vyvgart (efgartigimod alfa-fcab) the green light on 17 December on the back of data from the Phase III ADAPT trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Roche Reveals Another US Manufacturing Site As Tariff Pressures Seem To Ease

 
• By Mandy Jackson

Roche/Genentech unveiled plans for a $700m-plus manufacturing facility for weight loss drugs in North Carolina as President Trump signaled such investments could mean no tariffs for pharma.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.